CVR 33240171Limited partnership (K/S)Forskning og eksperimentel udvikling indenfor bioteknologi (721100)København KFounded 29 Sep 2010
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about ISAR PHARMA K/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexISAR PHARMA GENERAL PARTNER ApSCVR 33239580, until 28 Jun 2013
No current partner is registered.
Liable for the company's debts without limit (fuldt ansvarlige deltagere).
CVR 3323958029 Sep 2010 to 28 Jun 2013
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
Not available in the CVR filing: the annual reports carry no machine-readable figures.
Annual report 2011
29 Sep 2010 to 31 Dec 2011, published 23 May 2012
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for ISAR PHARMA K/S:
Have Pro? Sign in.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
8 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Retsform:
Kommanditselskab.
Virksomheden er slettet af registeret, jf. lov om visse erhvervsdrivende virksomheder § 12.
Retsform:
Kommanditselskab.
Ny adresse:
c/o Nordic Biotech Advisors ApS, Østergade 24, 1., 1100 København K.
Retsform:
Kommanditselskab.
Bestyrelse:
Udtrådt af bestyrelsen:
Jesper Ola Reidar Gusta, den 13.02.2013.
Indtrådt i bestyrelsen:
Direktør Florian Schønharting, den 13.02.2012.
Retsform:
Kommanditselskab.
Ny adresse:
c/o Intertrust Denmark, Havnegade 39, 1058 København K.
Retsform:
Kommanditselskab.
Bestyrelse:
Udtrådt af bestyrelsen:
Wyle David Solomon, den 22.05.2012.
Indtrådt i bestyrelsen:
Jesper Ola Reidar Gusta, den 22.05.2012.
Retsform:
Kommanditselskab.
Seneste vedtægtsdato:
29.09.2010.
Komplementar: CVR-NR. 33239580 ISAR PHARMA GENERAL PARTNER ApS, Østergade 24A, 1. tv., 1100 København K, den 29.09.2010.
Bestyrelse:
John M. Barberich, den 29.09.2010, Vice president Wyle David Solomon, den 29.09.2010.
Virksomheden tegnes af to bestyrelsesmedlemmer i forening, af den samlede bestyrelse eller af komplementaren.
Revision:
CVR-NR. 73317428 ERNST & YOUNG GODKENDT REVISIONSAKTIESELSKAB, Gyngemose Parkvej 50, 2860 Søborg, den 29.09.2010.
Første regnskabsår:
29.09.2010 - 31.12.2011.
Regnskabsår:
01.01 - 31.12.
P-number 1016355557Østergade 24, 1100 København K